

Set	Items	Description
S1	18159	BORDETELLA (1W) BRONCHISEPTICA
S2	22	S1 AND P68
S3	22	RD (unique items)

? t s3/3,ab/1-22

>>>No matching display code(s) found in file(s): 65, 129, 135, 180, 342, 345, 390, 398, 452-453, 764

3/3,AB/1 (Item 1 from file: 398)
 DIALOG(R)File 398:Chemsearch
 (c) 2006 Amer.Chem.Soc. All rts. reserv.

CAS REGISTRY NUMBER: 735855-89-7
 MOLECULAR FORMULA: Unknown
 CA NAME(S):
 HP=Antigen p68 (Bordetella bronchiseptica isoform) (9CI)
 SYNONYMS: Outer membrane protein p68 (Bordetella bronchiseptica isoform);
 Pertactin p68 (Bordetella bronchiseptica isoform); 3: PN: WO2004067031
 SEQID: 3 claimed protein

3/3,AB/2 (Item 2 from file: 398)
 DIALOG(R)File 398:Chemsearch
 (c) 2006 Amer.Chem.Soc. All rts. reserv.

CAS REGISTRY NUMBER: 735855-88-6
 MOLECULAR FORMULA: Unknown
 CA NAME(S):
 HP=DNA (Bordetella bronchiseptica antigen p68 gene) (9CI)
 SYNONYMS: DNA (Bordetella bronchiseptica outer membrane protein p68 gene)
 ; 2: PN: WO2004067031 SEQID: 2 claimed DNA

3/3,AB/3 (Item 3 from file: 398)
 DIALOG(R)File 398:Chemsearch
 (c) 2006 Amer.Chem.Soc. All rts. reserv.

CAS REGISTRY NUMBER: 735847-95-7
 MOLECULAR FORMULA: Unknown
 CA NAME(S):
 HP=Antigen p68 (Bordetella bronchiseptica) (9CI)
 SYNONYMS: Outer membrane protein p68 (Bordetella bronchiseptica);
 Pertactin p68 (Bordetella bronchiseptica); 1: PN: WO2004067031 SEQID: 1
 claimed protein

3/3,AB/4 (Item 1 from file: 654)
 DIALOG(R)File 654:US Pat.Full.
 (c) Format only 2006 Dialog. All rts. reserv.

6805810

UTILITY

Formulations and process for production of %Bordetella% %bronchiseptica%
 %P68% antigen and vaccines

Inventor: Dominowski, Paul J., Hickory Corners, MI, US
 Frantz, Joseph C., Nazareth, PA, US
 Krebs, Richard L., Ashland, NE, US
 Shields, Shelly L., Plainwell, MI, US
 Sorensen, Robert Greg, Lincoln, NE, US
 Galvin, Jeffrey E., Mattawan, MI, US

Assignee: Unassigned

Correspondence Address: PHARMACIA & UPJOHN, 7000 Portage Road, KZO-300-104,
 KALAMAZOO, MI, 49001, US

	Publication Number	Kind	Date	Application Number	Filing Date
Main Patent	US 20060251674	A1	20061109	US 2006393602	20060330
Provisional				US 60-669277	20050407

Fulltext Word Count: 14256

Abstract:

[00000] The present invention comprises new formulations and a process for making such formulations for vaccine compositions comprising a %Bordetella% %bronchiseptica% %p68% antigen.

3/3,AB/5 (Item 2 from file: 654)
 DIALOG(R)File 654:US Pat.Full.
 (c) Format only 2006 Dialog. All rts. reserv.

6077534

Derwent Accession: 2004-580858
 UTILITY

Canine vaccines against %Bordetella% %bronchiseptica%

Inventor: Frantz, Joseph, Denton, NE, US
 Tucker, Cassius McAllister, Kalamazoo, MI., US
 Newby, Thomas Jack, Bennet, NE, US

Assignee: Unassigned

Correspondence Address: Timothy J. Gumbleton;Pfizer, Inc., 301 Henrietta Street, Kalamazoo, MI, 49007, US

	Publication Number	Kind	Date	Application Number	Filing Date
Main Patent	US 20050089533	A1	20050428	US 2004959757	20041006
CIP	PENDING			US 2004767809	20040129
Provisional				US 60-443418	20030129

Fulltext Word Count: 23605

Abstract:

[00000] This invention relates to vaccines and methods for protecting dogs against disease caused by %Bordetella% %bronchiseptica%. This invention relates to vaccines and methods for protecting dogs against disease caused by Leptospira bratislava. This invention also relates to combination vaccines and methods for protecting dogs against disease or disorder caused by canine pathogens, for example, infectious tracheobronchitis caused by %Bordetella% %bronchiseptica%, canine distemper caused by canine distemper (CD) virus, infectious canine hepatitis (ICH) caused by canine adenovirus type 1 (CAV-1), respiratory disease caused by canine adenovirus type 2 (CAV-2), canine parainfluenza caused by canine parainfluenza (CPI) virus, enteritis caused by canine coronavirus (CCV) and canine parvovirus (CPV), and leptospirosis caused by Leptospira bratislava, Leptospira canicola, Leptospira grippotyphosa, Leptospira icterohaemorrhagiae or Leptospira pomona.

3/3,AB/6 (Item 3 from file: 654)
 DIALOG(R)File 654:US Pat.Full.
 (c) Format only 2006 Dialog. All rts. reserv.

0005805981

Derwent Accession: 2004-580858

Canine vaccines against %Bordetella% %bronchiseptica%

Inventor: Dominowski, Paul, INV

Frantz, Joseph, INV
Krebs, Richard, INV
Shields, Shelly, INV
Sorensen, Robert, INV

Correspondence Address: SCULLY SCOTT MURPHY & PRESSER, PC, 400 GARDEN CITY
PLAZA, GARDEN CITY, NY, 11530

	Publication Number	Kind	Date	Application Number	Filing Date
Main Patent	US 20040185062	A1	20040923	US 2004767809	20040129
Provisional				US 60-443418	20030129

Fulltext Word Count: 20075

Abstract:

This invention relates to vaccines and methods for protecting dogs against disease caused by %Bordetella% %bronchiseptica%. This invention also relates to combination vaccines and methods for protecting dogs against disease or disorder caused by canine pathogens, for example, infectious tracheobronchitis caused by %Bordetella% %bronchiseptica%, canine distemper caused by canine distemper (CD) virus, infectious canine hepatitis (ICH) caused by canine adenovirus type 1 (CAV-1), respiratory disease caused by canine adenovirus type 2 (CAV-2), canine parainfluenza caused by canine parainfluenza (CPI) virus, enteritis caused by canine coronavirus (CCV) and canine parvovirus (CPV), and leptospirosis caused by Leptospira Bratislava, Leptospira canicola, Leptospira grippotyphosa, Leptospira icterohaemorrhagiae or Leptospira pomona. The vaccines of the present invention include a %Bordetella% %bronchiseptica% %p68% antigen.

3/3,AB/7 (Item 4 from file: 654)
DIALOG(R)File 654:US Pat.Full.
(c) Format only 2006 Dialog. All rts. reserv.

4224834

Derwent Accession: 1991-126587

Utility

CERTIFICATE OF CORRECTION

C/ Polypeptides and vaccines for Bordetellapertussis and method of use

Inventor: Charles, Ian George, Kent, GB

Fairweather, Neti Fraser, Kent, GB

Assignee: Medeva Pharma Limited(03), Surrey, GB

Medeva Pharma Ltd GB (Code: 51377)

Examiner: Budens, Robert D. (Art Unit: 168)

Law Firm: Nixon & Vanderhye P.C.

	Publication Number	Kind	Date	Application Number	Filing Date
Main Patent	US 5976544	A	19991102	US 95474386	19950607
Continuation	Abandoned			US 94247544	19940523
Continuation	Abandoned			US 9348059	19930419
Continuation	Abandoned			US 91798045	19911127
Continuation	Abandoned			US 90576589	19900904
Priority				GB 8919940	19890904
				GB 9011358	19900521

Fulltext Word Count: 7417

Abstract:

A polypeptide for use in a vaccine against Bordetella pertussis, B. parapertussis or B. bronchiseptica contains an epitope selected from (a) the amino acid sequence coded for by nucleotides 1885 to 1902 of the P.69 gene of B. pertussis CN2992; (b) the corresponding amino acid sequence of another strain of B. pertussis or of a strain of B. parapertussis or B. bronchiseptica; and (c) a modified version of sequence (a) or (b) which has substantially the same antigenicity. The polypeptide is no more than 50 amino acid residues long or is a chimaeric protein composed of a carrier protein sequence and a sequence of no more than 50 amino acid residues which contains the required epitope.

3/3,AB/8 (Item 1 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2006 American Chemical Society. All rts. reserv.

145417017 CA: 145(21)417017v PATENT
Formulations and process for production of Bordetella bronchiseptica p68 antigen and vaccines
INVENTOR(AUTHOR): Dominowski, Paul Joseph; Frantz, Joseph Claude; Galvin, Jeffrey Ernest; Krebs, Richard Lee; Shields, Shelly Lynn; Sorensen, Robert Greg
LOCATION: USA
ASSIGNEE: Pharmacia & Upjohn Company LLC
PATENT: PCT International ; WO 2006106424 A2 DATE: 20061012
APPLICATION: WO 2006IB946 (20060328) *US 2005PV699277 (20050407)
PAGES: 50pp. CODEN: PIXXD2 LANGUAGE: English
PATENT CLASSIFICATIONS:
CLASS: A61K-000/A
DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BW; BY; BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; EG; ES; FI; GB; GD; GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KM; KN; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; LY; MA; MD; MG; MK; MN; MW; MX; MZ; NA; NG; NI; NO; NZ; OM; PG; PH; PL; PT; RO; RU; SC; SD; SE; SG; SK; SL; SM; SY; TJ; TM; TN; TR; TT; TZ; UA; UG; US; UZ; VC; VN; YU; ZA DESIGNATED REGIONAL: AT; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HU; IE; IS; IT; LT; LU; LV; MC; NL; PL; PT; RO; SE; SI; SK; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR; NE; SN; TD; TG; BW; GH; GM; KE; LS; MW; MZ; NA; SD; SL; SZ; TZ; UG; ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM

3/3,AB/9 (Item 2 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2006 American Chemical Society. All rts. reserv.

141172866 CA: 141(11)172866h PATENT
Bordetella bronchiseptica p68 antigen in combination with other pathogenic antigen as vaccines against canine diseases
INVENTOR(AUTHOR): Dominowski, Paul Joseph; Frantz, Joseph Claude; Krebs, Richard Lee; Shields, Shelly Lynn; Sorensen, Robert-Greg
LOCATION: USA
ASSIGNEE: Pfizer Products Inc.
PATENT: PCT International ; WO 200467031 A1 DATE: 20040812
APPLICATION: WO 2004IB146 (20040115) *US PV443418 (20030129)
PAGES: 78 pp. CODEN: PIXXD2 LANGUAGE: English
PATENT CLASSIFICATIONS:
CLASS: A61K-039/10A; A61K-039/295B; A61K-039/39B
DESIGNATED COUNTRIES: AE; AE; AG; AL; AL; AM; AM; AM; AT; AT; AU; AZ; AZ; BA; BB; BG; BG; BR; BR; BW; BY; BY; BZ; BZ; CA; CH; CN; CN; CO; CO; CR; CR; CU; CU; CZ; CZ; DE; DE; DK; DK; DM; DZ; EC; EC; EE; EE; EG; ES; ES; FI; FI; GB; GD; GE; GE; GH; GM; HR; HR; HU; HU; ID; IL; IN; IS; JP; JP; KE; KE; KG; KG; KP; KP; KR; KR; KR; KZ; KZ; LC; LC; LK; LR; LS; LS; LT; LU; LV; MA; MD; MD; MG; MK; MN; MW; MX; MX; MZ; MZ; NA; NI

3/3,AB/10 (Item 3 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2006 American Chemical Society. All rts. reserv.

119023000 CA: 119(3)23000q JOURNAL
Cloning, nucleotide sequence and heterologous expression of the
protective outer-membrane protein P.68 pertactin from Bordetella
bronchiseptica
AUTHOR(S): Li, Jingli; Fairweather, Neil F.; Novotny, Pavel; Dougan,
Gordon; Charles, Ian G.
LOCATION: Wellcome Res. Lab., Beckenham/Kent, UK, BR3 3BS
JOURNAL: J. Gen. Microbiol. DATE: 1992 VOLUME: 138 NUMBER: 8 PAGES:
1697-705 CODEN: JGMIAN ISSN: 0022-1287 LANGUAGE: English

3/3,AB/11 (Item 4 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2006 American Chemical Society. All rts. reserv.

118122975 CA: 118(13)122975x PATENT
Bordetella bronchiseptica outer membrane antigen
INVENTOR(AUTHOR): Charles, Ian George
LOCATION: UK,
ASSIGNEE: Wellcome Foundation Ltd.
PATENT: PCT International ; WO 9217587 A1 DATE: 921015
APPLICATION: WO 92GB561 (920327) *GB 916568 (910327)
PAGES: 28 pp. CODEN: PIXXD2 LANGUAGE: English
PATENT CLASSIFICATIONS:
CLASS: C12N-015/31A; C07K-013/00B; C12N-001/21B; A61K-039/10B
DESIGNATED COUNTRIES: JP; US DESIGNATED REGIONAL: AT; BE; CH; DE; DK; ES
; FR; GB; GR; IT; LU; MC; NL; SE

3/3,AB/12 (Item 1 from file: 349)
DIALOG(R)File 349:PCT FULLTEXT
(c) 2006 WIPO/Thomson. All rts. reserv.

01431190
NOVEL VACCINE FORMULATIONS
NOUVELLES FORMULATIONS DE VACCINS
Patent Applicant/Assignee:
MERIAL LIMITED, 3239 Satellite Blvd., Duluth, Georgia 30096, US, US
(Residence), US (Nationality), (For all designated states except: US)
Patent Applicant/Inventor:
PARISOT Alexis Guy Andre, 371 Rue Garibaldi, F-69007 Lyon, FR, FR
(Residence), FR (Nationality), (Designated only for: US)
DESGOUILLES-BLECHET Stephanie Marie-Catherine, 23 Rue Henri Gorjus,
F-69004 Lyon, FR, FR (Residence), FR (Nationality), (Designated only
for: US)
CHARREYRE Catherine, 42 Rue Ferdinand Gauthier, F-69720 Saint-Laurent De
Mure, FR, FR (Residence), FR (Nationality), (Designated only for: US)
ROULET Claude Jean Marie, 30 bis Avenue Francis de Pressense, F-69200
Venissieux, FR, FR (Residence), FR (Nationality), (Designated only for:
US)
Legal Representative:
JARECKI-BLACK Judy (agent), Merial Limited, 3239 Satellite Blvd., Duluth,
Georgia 30096, US
Patent and Priority Information (Country, Number, Date):
Patent: WO 2006113373 A2 20061026 (WO 06113373)
Application: WO 2006US13936 20060413 (PCT/WO US2006013936)
Priority Application: US 2005107000 20050415
Designated States:

(All protection types applied unless otherwise stated - for applications 2004+)

AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM
DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KN KP KR
KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG
PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC
VN YU ZA ZM ZW

(EP) AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL
PL PT RO SE SI SK TR

(OA) BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

(AP) BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW

(EA) AM AZ BY KG KZ MD RU TJ TM

Publication Language: English

Filing Language: English

Fulltext Word Count: 17001

English Abstract

The present invention relates to oil-in-water emulsions, their use as adjuvants, and pharmaceutical, immunologic, or vaccine compositions that may comprise the same. In one embodiment, the oil-in-water (OAV) emulsion may comprise an aqueous solution containing an immunogen, a mineral oil, a non-ionic lipophilic ethoxylated fatty alcohol and a non-ionic hydrophilic surfactant. In another embodiment, the oil-in-water (OAV) emulsion may comprise an aqueous solution containing an immunogen, a non-ionic lipophilic surfactant, a mineral oil and a non-ionic hydrophilic ethoxylated fatty alcohol. The present invention also encompasses a method of making a vaccine composition using the adjuvant of the instant invention, the vaccine composition so obtained and methods of use.

French Abstract

La presente invention concerne des emulsions huile dans l'eau, leur utilisation en tant qu'additifs, et des compositions pharmaceutiques, immunologiques ou de vaccination qui comprennent ces emulsions. Dans un mode de realisation, l'emulsion huile dans l'eau (oil-in-water / OAV) peut comprendre une solution aqueuse qui contient un immunogene, une huile minerale, un alcool gras ethoxyle lipophile non ionique et un tensioactif hydrophile non ionique. Dans un autre mode de realisation, l'emulsion huile dans l'eau (OAV) peut comprendre une solution aqueuse contenant un immunogene, un tensioactif lipophile non ionique, une huile minerale et un alcool gras ethoxyle hydrophile non ionique. L'invention a egalement pour objet un procede pour produire une composition de vaccination au moyen de l'additif de l'invention, la composition ainsi obtenue, et des procedes d'utilisation.

3/3,AB/13 (Item 2 from file: 349)

DIALOG(R)File 349:PCT FULLTEXT

(c) 2006 WIPO/Thomson. All rts. reserv.

01426023

FORMULATIONS AND PROCESS FOR PRODUCTION OF %BORDETELLA% %BRONCHISEPTICA%
%P68% ANTIGEN AND VACCINES

FORMULATIONS ET PROCEDE DE PRODUCTION DE L'ANTIGENE %P68% NATIF DE
%BORDETELLA% %BRONCHISEPTICA% %P68% ET DE FABRICATION DE VACCINS

Patent Applicant/Assignee:

PHARMACIA & UPJOHN COMPANY LLC, 7000 Portage Road, Kalamazoo, MI
49001-0199, US, US (Residence), US (Nationality), (For all designated
states except: US)

Patent Applicant/Inventor:

DOMINOWSKI Paul Joseph, Pfizer Global Research and Development, 7000
Portage Road, Kalamazoo, MI 49001-0199, US, US (Residence), US
(Nationality), (Designated only for: US)

FRANTZ Joseph Claude, Pfizer Global Research and Development, European

Patent Department, Ramsgate Road, Sandwich, Kent CT13 9NJ, US, US
(Residence), US (Nationality), (Designated only for: US)
GALVIN Jeffrey Ernest, Pfizer Global Research and Development, 7000
Portage Road, Kalamazoo, MI 49001-0199, US, US (Residence), US
(Nationality), (Designated only for: US)
KREBS Richard Lee, Pfizer Global Research and Development, 7000 Portage
Road, Kalamazoo, MI 49001-0199, US, US (Residence), US (Nationality),
(Designated only for: US)
SHIELDS Shelly Lynn, Pfizer Global Research and Development, 7000 Portage
Road, Kalamazoo, MI 49001-0199, US, US (Residence), US (Nationality),
(Designated only for: US)
SORENSEN Robert Greg, Pfizer Global Reserach and Development, Henrietta
Street, Kalamazoo, MI 49007, US, US (Residence), US (Nationality),
(Designated only for: US)

Legal Representative:

FULLER Grover F Jr (agent), c/o Drouin, Stephane, Pfizer Global Research,
and Development, Ramsgate Road, Kent CT13 9NJ, GB

Patent and Priority Information (Country, Number, Date):

Patent: WO 2006106424 A2 20061012 (WO 06106424)
Application: WO 2006IB946 20060328 (PCT/WO IB2006000946)
Priority Application: US 2005699277 20050407

Designated States:

(All protection types applied unless otherwise stated - for applications
2004+)

AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM
DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KN KP KR
KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG
PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC
VN YU ZA ZM ZW

(EP) AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL
PL PT RO SE SI SK TR

(OA) BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

(AP) BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW

(EA) AM AZ BY KG KZ MD RU TJ TM

Publication Language: English

Filing Language: English

Fulltext Word Count: 15601

English Abstract

The present invention comprises new formulations and a process for making
such formulations for vaccine compositions comprising a %Bordetella%
%bronchiseptica% %p68% antigen.

French Abstract

Cette invention concerne de nouvelles formulations ainsi qu'un procede de
fabrication desdites formulations destinees a des compositions de vaccins
comprenant un antigene %p68% natif de %Bordetella% %bronchiseptica%.

3/3,AB/14 (Item 3 from file: 349)

DIALOG(R)File 349:PCT FULLTEXT

(c) 2006 WIPO/Thomson. All rts. reserv.

01355873

MULTIVALENT CANINE VACCINES AGAINST LEPTOSPIRA BRATISLAVA AND OTHER
PATHOGENS

VACCINS CANINS MULTIVALENTS CONTRE %BORDETELLA% %BRONCHISEPTICA% ET AUTRES
AGENTS PATHOGENES

Patent Applicant/Assignee:

PFIZER PRODUCTS INC, Eastern Point Road, Groton, CT 06340, US, US
(Residence), US (Nationality), (For all designated states except: US)

Patent Applicant/Inventor:

FRANTZ Joseph, c/o Pfizer Inc., 601 West Cornhusker Highway, Lincoln, NE
68501, US, US (Residence), US (Nationality), (Designated only for: US)

NEWBY Thomas Jack, c/o Pfizer Inc., 601 West Cornhusker Highway, Lincoln,
NE 68501, US, US (Residence), US. (Nationality), (Designated only for:
US)

TUCKER Cassius McAllister, c/o Pfizer Global Research and Development,
301 Henrietta Street, Kalamazoo, MI 49001, US, US (Residence), US
(Nationality), (Designated only for: US)

Legal Representative:

FULLER Grover F et al (agent), c/o DROUIN, Stephane, European Pharma
Patent Department, Pfizer Global Research and Development, Ramsgate
Road, Sandwich, Kent CT13 9NJ, GB

Patent and Priority Information (Country, Number, Date):

Patent: WO 200638115 A1 20060413 (WO 0638115)
Application: WO 2005IB3111 20050923 (PCT/WO IB2005003111)
Priority Application: US 2004959757 20041006

Designated States:

(All protection types applied unless otherwise stated - for applications
2004+)

AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM
DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ
LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH
PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN
YU ZA ZM ZW

(EP) AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL
PL PT RO SE SI SK TR

(OA) BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

(AP) BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW

(EA) AM AZ BY KG KZ MD RU TJ TM

Publication Language: English

Filing Language: English

Fulltext Word Count: 31106

English Abstract

This invention relates to vaccines and methods for protecting dogs
against disease caused by *Leptospira bratislava*. This invention also
relates to combination vaccines and methods for protecting dogs against
disease or disorder caused by canine pathogens, for example, infectious
tracheobronchitis caused by *Bordetella bronchiseptica*, canine
distemper caused by canine distemper (CD) virus, infectious canine
hepatitis (ICH) caused by canine adenovirus type 1 (CAV-1), respiratory
disease caused by canine adenovirus type 2 (CAV-2), canine parainfluenza
caused by canine parainfluenza (CPI) virus, enteritis caused by canine
coronavirus (CCV) and canine parvovirus (CPV), and leptospirosis caused
by *Leptospira bratislava*, *Leptospira canicola*, *Leptospira grippotyphosa*,
Leptospira icterohaemorrhagiae or *Leptospira pomona*.

French Abstract

L'invention concerne des vaccins et des methodes de protection de chiens
contre une maladie provoquee par la bordetellose feline. (*Bordetella*
bronchiseptica). Cette invention a aussi pour objet des melanges de
vaccins et des methodes de protection de chiens contre une maladie ou un
trouble provoque par des agents pathogenes canins, par exemple, une
tracheo-bronchite infectieuse causee par la bordetellose feline, la
maladie de Carre engendree par le virus de cette meme maladie, une
hepatite canine infectieuse causee par l'adenovirus canin de type
1 (CAV-1), une maladie respiratoire provoquee par l'adenovirus canin de
type 2 (CAV-2), la parainfluenza canine engendree par le virus de la
parainfluenza canine, l'enterite provoquee par le coronavirus canin et le
parvovirus canin, et la leptospirose causee par *Leptospira bratislava*,
Leptospira canicola, *Leptospira grippotyphosa*, *Leptospira*
icterohaemorrhagiae ou *Leptospira pomona*.

(c) 2006 WIPO/Thomson. All rts. reserv.

01146763

CANINE VACCINES AGAINST BORDETELLA BRONCHISEPTICA

VACCINS CANINS CONTRE LA <I>BORDETELLA BRONCHISEPTICA</I>

Patent Applicant/Assignee:

PFIZER PRODUCTS INC, Eastern Point Road, Groton, CT 06340, US, US

(Residence), US (Nationality), (For all designated states except: US)

Patent Applicant/Inventor:

DOMINOWSKI Paul Joseph, Pfizer Global Research and Development, 301

Henrietta Street, Kalamazoo, MI 49001, US, US (Residence), US

(Nationality), (Designated only for: US)

FRANTZ Joseph Claude, Pfizer Inc, 601 West Cornhusker Highway, Lincoln,

NE 68501, US, US (Residence), US (Nationality), (Designated only for:

US)

KREBS Richard Lee, Pfizer Inc, 601 West Cornhusker Highway, Lincoln, NE

68501, US, US (Residence), US (Nationality), (Designated only for: US)

SHIELDS Shelly Lynn, Pfizer Global Research and Development, 301

Henrietta Street, Kalamazoo, MI 49001, US, US (Residence), US

(Nationality), (Designated only for: US)

SORENSEN Robert Greg, Pfizer Inc, 601 West Cornhusker Highway, Lincoln,

NE 68501, US, US (Residence), US (Nationality), (Designated only for:

US)

Legal Representative:

LUMB J Trevor (agent), Pfizer Global Research And Development, Uk Patent

Department, Ramsgate Road, Sandwich, Kent CT13 9NJ, GB,

Patent and Priority Information (Country, Number, Date):

Patent: WO 200467031 A1 20040812 (WO 0467031)

Application: WO 2004IB146 20040115 (PCT/WO IB04000146)

Priority Application: US 2003443418 20030129

Designated States:

(All protection types applied unless otherwise stated - for applications 2004+)

AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM
DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC
LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO
RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW
(EP) AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE
SI SK TR

(OA) BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

(AP) BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW

(EA) AM AZ BY KG KZ MD RU TJ TM

Publication Language: English

Filing Language: English

Fulltext Word Count: 22608

English Abstract

This invention relates to vaccines and methods for protecting dogs against disease caused by Bordetella bronchiseptica. This invention also relates to combination vaccines and methods for protecting dogs against disease or disorder caused by canine pathogens, for example, infectious tracheobronchitis caused by Bordetella bronchiseptica, canine distemper caused by canine distemper (CD) virus, infectious canine hepatitis (ICH) caused by canine adenovirus type 1 (CAV-1), respiratory disease caused by canine adenovirus type 2 (CAV-2), canine parainfluenza caused by canine parainfluenza (CPI) virus, enteritis caused by canine coronavirus (CCV) and canine parvovirus (CPV), and leptospirosis caused by Leptospira Bratislava, Leptospira canicola, Leptospira grippotyphosa, Leptospira icterohaemorrhagiae or Leptospira pomona. The vaccines of the present invention include a Bordetella bronchiseptica p68 antigen.

French Abstract

L'invention concerne des vaccins et des procedes permettant de proteger les chiens contre la maladie provoquee par la Bordetella Bronchiseptica.

Elle concerne également des vaccins de combinaison et des procedes pour proteger les chiens contre la maladie ou des troubles provoques par des pathogenes canins, par exemple, la tracheobronchite infectieuse provoquee par la Bordetella Bronchiseptica, la maladie de Carre provoquee par le virus (CDV), l'hepatite canine infectieuse (ICH) provoquee par l'adenovirus canin type 1 (CAV-1), la maladie respiratoire provoquee par l'adenovirus canin type 2 (CAV-2), la parainfluenza provoquee par le virus de la parainfluenza canine (CPI), l'enterite provoquee par le coronavirus canin (CCV) et le parvovirus canin (CPV), ainsi que la leptospirose provoquee par leptospira Bratislava, leptospira grippotyphosa, leptospira icterohaemorrhagiae ou leptospira pomona. Les vaccins selon l'invention comprennent un antigene Bordetella bronchiseptica p68.

3/3,AB/16 (Item 5 from file: 349)
DIALOG(R)File 349:PCT FULLTEXT
(c) 2006 WIPO/Thomson. All rts. reserv.

00834529

HUMAN GENES AND GENE EXPRESSION PRODUCTS
NOUVEAUX GENES HUMAINS ET LEURS PRODUITS D'EXPRESSION

Patent Applicant/Assignee:

CHIRON CORPORATION, R-440, 4560 Horton Street, Emeryville, CA 94608, US,
US (Residence), US (Nationality), (For all designated states except:
US)

HYSEQ INC, 675 Almanor Avenue, Sunnyvale, CA 94086, US, US (Residence),
US (Nationality), (For all designated states except: US)

Patent Applicant/Inventor:

WILLIAMS Lewis T, 125 Chapel Drive, Mill Valley, CA 94920, US, US
(Residence), US (Nationality), (Designated only for: US)

ESCOBEDO Jaime, 1470 Lavana Road, Alamo, CA 94507, US, US (Residence),
CL (Nationality), (Designated only for: US)

INNIS Michael A, 315 Constance Place, Moraga, CA 94556, US, US
(Residence), US (Nationality), (Designated only for: US)

GARCIA Pablo Dominguez, 882 Chenery Street, San Francisco, CA 94131, US,
US (Residence), CL (Nationality), (Designated only for: US)

SUDDUTH-KLINGER Julie, 280 Lexington Road, Kensington, CA 94707, US, US
(Residence), US (Nationality), (Designated only for: US)

REINHARD Christoph, 1633 Clinton Avenue, Alameda, CA 94501, US, US
(Residence), DE (Nationality), (Designated only for: US)

RANDAZZO Filippo, 104 Capricorn Avenue, Oakland, California 94611, US, US
(Residence), US (Nationality), (Designated only for: US)

KENNEDY Giulia C, 360 Castenada Avenue, San Francisco, CA 94116, US, US
(Residence), US (Nationality), (Designated only for: US)

POT David, 5550 Columbia Pike, #915, Arlington, VA 22204, US, US
(Residence), CA (Nationality), (Designated only for: US)

KASSAM Altaf, 3810 Midvale Avenue, Oakland, CA 94602, US, US (Residence),
US (Nationality), (Designated only for: US)

LAMSON George, 232 Sandringham Drive, Moraga, CA 94556, US, US
(Residence), US (Nationality), (Designated only for: US)

DRMANAC Radoje, 850 East Greenwich Place, Palo Alto, CA 94303, US, US
(Residence), YU (Nationality), (Designated only for: US)

CRKVENJAKOV Radomir, 762 Haverhill Drive, Sunnyvale, CA 94068, US, US
(Residence), YU (Nationality), (Designated only for: US)

DICKSON Mark, 1411 Gabilan Drive #B, Hollister, CA 95025, US, US
(Residence), US (Nationality), (Designated only for: US)

DRMANAC Snezana, 850 East Greenwich Place, Palo Alto, CA 94303, US, US
(Residence), YU (Nationality), (Designated only for: US)

LABAT Ivan, 1006 Asbury Way, Mountain View, CA 94043, US, US (Residence),
YU (Nationality), (Designated only for: US)

LESHKOWITZ Dena, 1 Mevo Brosh, Yehud, 56452, IL, IL (Residence), US
(Nationality), (Designated only for: US)

KITA David, 899 Bounty Drive, Foster City, CA 94404, US, US (Residence),

US (Nationality), (Designated only for: US)
GARCIA Veronica, 396 Ano Nuevo, Apt. 412, Sunnyvale, CA 94086, US, US
(Residence), ES (Nationality), (Designated only for: US)
JONES William Lee, 396 Ano Nuevo #412, Sunnyvale, CA 94086, US, US
(Residence), US (Nationality), (Designated only for: US)
STACHE-CRAIN Birgit, 345 South Mary Avenue, Sunnyvale, CA 94086, US, US
(Residence), DE (Nationality), (Designated only for: US)

Legal Representative:

BLACKBURN Robert P (agent), Chiron Corporation, P.O. Box 8097,
Emeryville, CA 94662-8097, US,

Patent and Priority Information (Country, Number, Date):

Patent: WO 200166753 A2-A3 20010913 (WO 0166753)
Application: WO 2001US7787 20010309 (PCT/WO US0107787)
Priority Application: US 2000188609 20000309

Designated States:

(Protection type is "patent" unless otherwise stated - for applications prior to 2004).

AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ
EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS
LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ
TM TR TT TZ UA UG US UZ VN YU ZA ZW

(EP) AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

(OA) BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

(AP) GH GM KE LS MW MZ SD SL SZ TZ UG ZW

(EA) AM AZ BY KG KZ MD RU TJ TM

Publication Language: English

Filing Language: English

Fulltext Word Count: 182260

English Abstract

This invention relates to novel human polynucleotides and variants thereof, their encoded polypeptides and variants thereof, to genes corresponding to these polynucleotides and to proteins expressed by the genes. The invention also relates to diagnostic and therapeutic agents employing such novel human polynucleotides, their corresponding genes or gene products, e.g., these genes and proteins, including probes, antisense constructs, and antibodies.

French Abstract

L'invention porte sur de nouveaux polynucleotides humains et leurs variantes, sur les polypeptides codes par eux et leurs variantes, sur les genes correspondant a ces polynucleotides, et sur des proteines exprimees par ces genes. L'invention porte egalement sur des agents diagnostiques et therapeutiques utilisant lesdits nouveaux polynucleotides humains et les genes et produits geniques correspondants, ces genes et proteines comportant des sondes, des produits d'assemblage et des anticorps.

3/3,AB/17 (Item 1 from file: 348)
DIALOG(R)File 348:EUROPEAN PATENTS
(c) 2006 European Patent Office. All rts. reserv.

00502608

EXPRESSION OF BORDETELLA PERTACTIN ANTIGENS IN PICHIA
EXPRESSION VON BORDETELLA ANTIGENEN IN PICHIA
EXPRESSION DES ANTIGENS DE BORDETELLA DANS LA LEVURE PICHIA
PATENT ASSIGNEE:

Medeva Pharma Limited, (1946511), Evans House, Regent Park, Kingston Road
, Leatherhead, Surrey KT22 7PQ, (GB), (applicant designated states:
AT;BE;CH;DE;DK;ES;FR;GB;GR;IT;LI;LU;NL;SE)

INVENTOR:

CLARE, Jeffrey, John Langley Court, Beckenham, Kent BR3 3BS, (GB)
ROMANOS, Michael, Anthony Langley Court, Beckenham, Kent BR3 3BS, (GB)

LEGAL REPRESENTATIVE:

Woods, Geoffrey Corlett et al (48721), J.A. KEMP & CO. 14 South Square
Gray's Inn, London WC1R 5LX, (GB)
PATENT (CC, No, Kind, Date): EP 527752 A1 930224 (Basic)
EP 527752 B1 990512
WO 9115571 911017
APPLICATION (CC, No, Date): EP 91906598 910328; WO 91GB487 910328
PRIORITY (CC, No, Date): GB 9007416 900402
DESIGNATED STATES: AT; BE; CH; DE; DK; ES; FR; GB; GR; IT; LI; LU; NL; SE
INTERNATIONAL PATENT CLASS (V7): C12N-001/19; C12N-015/81; C12N-015/31;
C12N-001/19; C12R-001/84
NOTE:

No A-document published by EPO
LANGUAGE (Publication,Procedural,Application): English; English; English
FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS B	(English)	9919	535
CLAIMS B	(German)	9919	468
CLAIMS B	(French)	9919	530
SPEC B	(English)	9919	4228
Total word count - document A			0
Total word count - document B			5761
Total word count - documents A + B			5761

3/3,AB/18 (Item 1 from file: 357)
DIALOG(R)File 357:Derwent Biotech Res.
(c) 2006 The Thomson Corp. All rts. reserv.

0346818 DBR Accession No.: 2004-19110 PATENT
New vaccine composition comprising %Bordetella% %bronchiseptica% %p68%
antigen and an adjuvant, useful for immunizing dogs against canine
pathogens, e.g., %Bordetella% %bronchiseptica%, canine distemper virus
or Leptospira Pomona - recombinant vaccine production
AUTHOR: DOMINOWSKI P J; FRANTZ J C; KREBS R L; SHIELDS S L; SORENSEN R
G
PATENT ASSIGNEE: PFIZER PROD INC 2004
PATENT NUMBER: WO 200467031 PATENT DATE: 20040812 WPI ACCESSION NO.:
2004-580858 (200456)
PRIORITY APPLIC. NO.: US 443418 APPLIC. DATE: 20030129
NATIONAL APPLIC. NO.: WO 2004IB146 APPLIC. DATE: 20040115
LANGUAGE: English

ABSTRACT: DERWENT ABSTRACT: NOVELTY - A new vaccine composition comprises
%Bordetella% %bronchiseptica% %p68% antigen and an adjuvant effective
to protect dogs against %Bordetella% %bronchiseptica%. DETAILED
DESCRIPTION - An INDEPENDENT CLAIM is included for a method of
protecting dogs against %Bordetella% %bronchiseptica%. BIOTECHNOLOGY -
Preferred Vaccine Composition: The vaccine composition comprises
%Bordetella% %bronchiseptica% %p68% antigen and an adjuvant effective
to protect dogs against %Bordetella% %bronchiseptica%. The %Bordetella%
%bronchiseptica% %p68% antigen comprises the 602-amino acid sequence
and is produced recombinantly. The adjuvant comprises Quil A and
cholesterol. The vaccine is a combination vaccine for immunizing dogs
against canine pathogens and comprises: (a) a preparation of an
attenuated strain of canine distemper (CD) virus, an attenuated strain
of canine adenovirus type 2 (CAV-2), an attenuated strain of canine
parainfluenza (CPI) virus and an attenuated strain of canine parvovirus
(CPV); (b) an inactivated whole or partial cell preparation of a strain
of canine coronavirus (CCV); (c) a %Bordetella% %bronchiseptica% %p68%
protein; (d) a Leptospira bacterin comprising a Leptospira cell
preparation of at least one Leptospira species consisting of Leptospira
ipoptypfosa, Leptospira bratislava, Leptospira canicola, Leptospira
grippytypfosa, Leptospira icterhaemorrhagiae and Leptospira Pomona; and
(e) an adjuvant. Preferred Method: Protecting dogs against %Bordetella%
%bronchiseptica% comprises administering to a dog the vaccine

composition. ACTIVITY - Virucide. The experimental vaccine antigen was a recombinant %p68% outer membrane protein comprising 602-amino acid sequence of the %Bordetella% %bronchiseptica% produced by Escherichia coli strain LW68. Sixty male and female canine puppies were randomly allocated to one of six treatment groups (10 per group). Animals were vaccinated on Day 0 with either the placebo or the experimental vaccine. A second vaccine was administered on Day 21. The first vaccine was administered subcutaneously in the right neck and the second vaccine was administered subcutaneously in the left neck. All animals were challenged 28 days after the second vaccination with an aerosol of %Bordetella% %bronchiseptica%. The vaccinated dogs coughed significantly less than the placebo. MECHANISM OF ACTION - Vaccine. USE - The vaccine is useful for immunizing dogs against canine pathogens, e.g., canine distemper (CD) virus, canine adenovirus type 2 (CAV-2), canine parainfluenza (CPI) virus, canine parvovirus (CPV), canine coronavirus (CCV), %Bordetella% %bronchiseptica%, Leptospira ippotyphosa, Leptospira bratislava, Leptospira canicola, Leptospira grippotyphosa, Leptospira icterhaemorrhagiae or Leptospira Pomona. ADMINISTRATION - Dosage comprises 15-25 micrograms/kg body weight. The composition is administered via oral or parenteral route. EXAMPLE - No relevant examples given.(78 pages)

3/3,AB/19 (Item 1 from file: 340)
DIALOG(R)File 340:CLAIMS(R)/US Patent
(c) 2006 IFI/CLAIMS(R). All rts. reserv.

Dialog Acc No: 11302609 IFI Acc No: 2006-0251674
IFI Publication Control No: 2006-0251674 IFI Chemical Acc No: 2006-0056713
Document Type: C
FORMULATIONS AND PROCESS FOR PRODUCTION OF %BORDETELLA% %BRONCHISEPTICA%
%P68% ANTIGEN AND VACCINES
Inventors: Dominowski Paul J (US); Frantz Joseph C (US); Galvin Jeffrey E
(US); Krebs Richard L (US); Shields Shelly L (US); Sorensen Robert Greg
(US)
Assignee: Unassigned Or Assigned To Individual
Assignee Code: 68000
Attorney, Agent or Firm: PHARMACIA & UPJOHN, 7000 Portage Road, KZO-300-104
, KALAMAZOO, MI, 49001, US
Publication (No,Kind,Date), Applic (No,Date):
US 20060251674 A1 20061109 US 2006393602 20060330
Priority Applic(No,Date): US 2006393602 20060330
Provisional Applic(No,Date): US 60-669277 20050407

.Abstract: The present invention comprises new formulations and a process for making such formulations for vaccine compositions comprising a %Bordetella% %bronchiseptica% %p68% antigen.

3/3,AB/20 (Item 2 from file: 340)
DIALOG(R)File 340:CLAIMS(R)/US Patent
(c) 2006 IFI/CLAIMS(R). All rts. reserv.

Dialog Acc No: 10677823
IFI Chemical Acc No: 2004-0052771
Document Type: C
CANINE VACCINES AGAINST %BORDETELLA% %BRONCHISEPTICA%; COMPRISING
%BORDETELLA% %BRONCHISEPTICA% %P68% ANTIGEN AND ADJUVANT; VETERINARY
MEDICINE
Inventors: Dominowski Paul J (US); Frantz Joseph C (US); Krebs Richard L
(US); Shields Shelly L (US); Sorensen Robert Greg (US)
Assignee: Unassigned Or Assigned To Individual
Assignee Code: 68000
Probable Assignee: Pfizer Inc

Attorney, Agent or Firm: SCULLY SCOTT MURPHY & PRESSER, PC, 400 GARDEN CITY
PLAZA, GARDEN CITY, NY, 11530, US
Publication (No,Kind,Date), Applic (No,Date):
US 20040185062 A1 20040923 US 2004767809 20040129
Priority Applic(No,Date): US 2004767809 20040129
Provisional Applic(No,Date): US 60-443418 20030129

Abstract: This invention relates to vaccines and methods for protecting dogs against disease caused by %Bordetella% %bronchiseptica%. This invention also relates to combination vaccines and methods for protecting dogs against disease or disorder caused by canine pathogens, for example, infectious tracheobronchitis caused by %Bordetella% %bronchiseptica%, canine distemper caused by canine distemper (CD) virus, infectious canine hepatitis (ICH) caused by canine adenovirus type 1 (CAV-1), respiratory disease caused by canine adenovirus type 2 (CAV-2), canine parainfluenza caused by canine parainfluenza (CPI) virus, enteritis caused by canine coronavirus (CCV) and canine parvovirus (CPV), and leptospirosis caused by Leptospira Bratislava, Leptospira canicola, Leptospira grippotyphosa, Leptospira icterohaemorrhagiae or Leptospira pomona. The vaccines of the present invention include a %Bordetella% %bronchiseptica% %p68% antigen.

3/3,AB/21 (Item 3 from file: 340)
DIALOG(R)File 340:CLAIMS(R)/US Patent
(c) 2006 IFI/CLAIMS(R). All rts. reserv.

Dialog Acc No: 3227267 IFI Acc No: 9937024
IFI Publication Control No: 9937024
Document Type: C
POLYPEPTIDES AND VACCINES FOR BORDETELLAPERTUSSIS AND METHOD OF USE
Inventors: Charles Ian George (GB); Fairweather Neti Fraser (GB)
Assignee: Medeva Pharma Ltd GB
Assignee Code: 51377
Attorney, Agent or Firm: Nixon & Vanderhye P.C.
Publication (No,Kind,Date), Applic (No,Date):
US 5976544 A 19991102 US 95474386 19950607
Calculated Expiration: 20161102
(Cited in 001 later patents)
Document Type: CERTIFICATE OF CORRECTION
Certificate of Correction Date: 20000808
Priority Applic(No,Date): GB 8919940 19890904; GB 9011358
19900521

Abstract: A polypeptide for use in a vaccine against Bordetella pertussis, B. parapertussis or B. bronchiseptica contains an epitope selected from (a) the amino acid sequence coded for by nucleotides 1885 to 1902 of the P.69 gene of B. pertussis CN2992; (b) the corresponding amino acid sequence of another strain of B. pertussis or of a strain of B.parapertussis or B. bronchiseptica; and (c) a modified version of sequence (a) or (b) which has substantially the same antigenicity. The polypeptide is no more than 50 amino acid residues long or is a chimaeric protein composed of a carrier protein sequence and a sequence of no more than 50 amino acid residues which contains the required epitope.

3/3,AB/22 (Item 1 from file: 342)
DIALOG(R)File 342:Derwent Patents Citation Indx
(c)2006 The Thomson Corp. All rts. reserv.

06067417 WPI Acc No: 04-580858/56
New vaccine composition comprising Bordetella bronchiseptica p68 antigen and an adjuvant, useful for immunizing dogs against canine pathogens, e.g., Bordetella bronchiseptica, canine distemper virus or Leptospira Pomona -
Patent Assignee: (PFIZ) PFIZER PROD INC

Author (Inventor): DOMINOWSKI P J; FRANTZ J C; KREBS R L; SHIELDS S L;
SORENSEN R G

Patent (basic)

Patent No Kind Date Examiner Field of Search

WO 200467031 A1 040812 (BASIC) None

Derwent Week (Basic): 0456

Priority Data: US 443418P (030129)

Applications: AU 2004208556 (040115); BR 20047032 (040115); EP 2004702384
(040115); WO 2004IB146 (040115); JP 2005518725 (040115); US 767809 (
040129); US 959757 (041006); MX 8051 (050728); ZA 20056073 (050728); NO
20053734 (050803)

Designated States

(National): AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BW; BY; BZ; CA;
CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; EG; ES; FI; GB; GD; GE
; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR;
LS; LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; MZ; NA; NI; NO; NZ; OM; PG
; PH; PL; PT; RO; RU; SC; SD; SE; SG; SK; SL; SY; TJ; TM; TN; TR; TT;
TZ; UA; UG; US; UZ; VC; VN; YU; ZA; ZM; ZW

(Regional): AL; AT; BE; BG; BW; CH; CY; CZ; DE; DK; EA; EE; ES; FI; FR;
GB; GH; GM; GR; HU; IE; IT; KE; LI; LS; LT; LU; LV; MC; MK; MW; MZ; NL
; OA; PT; RO; SD; SE; SI; SK; SL; SZ; TR; TZ; UG; ZM; ZW

Derwent Class: B04; C06; D16

Int Pat Class: A61K-039/02; A61K-039/10; A61K-039/155; A61K-039/175;
A61K-039/215; A61K-039/23; A61K-039/235; A61K-039/295; A61K-039/39;
A61K-047/26; A61K-047/28

Number of Patents: 010

Number of Countries: 109

Number of Cited Patents: 005

Number of Cited Literature References: 004

Number of Citing Patents: 002

?

** DIALINDEX search results display in an abbreviated ***
 *** format unless you enter the SET DETAIL ON command. ***
 ? sf allscience
 You have 297 files in your file list.
 (To see banners, use SHOW FILES command)
 ? s bordetella (1w) bronchiseptica

Your SELECT statement is:
 s bordetella (1w) bronchiseptica

Items	File
1	2: INSPEC_1898-2006/Nov W1
1385	5: Biosis Previews(R)_1969-2006/Nov W2
7	6: NTIS_1964-2006/Nov W1
8	8: Ei Compendex(R)_1884-2006/Nov W1
529	10: AGRICOLA_70-2006/Nov
1	15: ABI/Inform(R)_1971-2006/Nov 18
4	16: Gale Group PROMT(R)_1990-2006/Nov 20
3	18: Gale Group F&S Index(R)_1988-2006/Nov 20
2	19: Chem.Industry Notes_1974-2006/ISS 200646
9	20: Dialog Global Reporter_1997-2006/Nov 17
566	24: CSA Life Sciences Abstracts_1966-2006/Oct
2	28: Oceanic Abstracts_1966-2006/Oct
735	34: SciSearch(R) Cited Ref Sci_1990-2006/Nov W2
40	35: Dissertation Abs Online_1861-2006/Oct
2	36: MetalBase_1965-20061114
12	45: EMCare_2006/Nov W2
5	47: Gale Group Magazine DB(TM)_1959-2006/Nov 20
1473	50: CAB Abstracts_1972-2006/Oct
8	51: Food Sci.&Tech.Abs_1969-2006/Nov W2
1	52: TSCA Chemical Substances Inventory 2003/OCT
33	65: Inside Conferences_1993-2006/Nov 17
269	71: ELSEVIER BIOBASE_1994-2006/Nov W2
720	73: EMBASE_1974-2006/Nov 17
12	74: Int.Pharm.Abs_1970-2006/Nov B2
Examined 50 files	
2	91: MANTIS(TM)_1880-2006/Jan
1	92: IHS Intl.Stds.& Specs._1999/Nov
79	94: JICST-EPlus_1985-2006/Jul W5
35	98: General Sci Abs_1984-2006/Oct
6	103: Energy SciTec_1974-2006/Sep B1
1	107: Adis R&D Insight_1986-2006/Sep W1
1	113: European R&D Database_1997
2	124: CLAIMS/REFERENCE_2001/2005Q4
1	128: PHARMAPROJECTS_1980-2006/Oct W5
122	129: PHIND(Archival)_1980-2006/Nov W2
18	135: NewsRx Weekly Reports_1995-2006/Nov W2
73	143: Biol. & Agric. Index_1983-2006/Sep
461	144: Pascal_1973-2006/Oct W4
7	148: Gale Group Trade & Industry DB_1976-2006/Nov 20
25	149: TGG Health&Wellness DB(SM)_1976-2006/Nov W1
915	155: MEDLINE(R)_1950-2006/Nov 14
158	156: ToxFile_1965-2006/Nov W1
7	160: Gale Group PROMT(R)_1972-1989
120	162: Global Health_1983-2006/Oct
3	164: Allied & Complementary Medicine_1984-2006/Nov
6	172: EMBASE Alert_2006/Nov 17
Examined 100 files	
1	177: Adv.& Agency Red Books:Advertisers_2006/Nov
28	180: Federal Register_1985-2006/Nov 17
2	183: Regulatory Affairs Journals_2003-2006/Nov 17
14	185: Zoological Record Online(R)_1978-2006/Nov
360	203: AGRIS_1974-2006/Sep

2 229: Drug Info. Fulltext_2002
 14 266: FEDRIP_2006/Aug
 22 285: BioBusiness(R)_1985-1998/Aug W1
 5 292: GEOBASE(TM)_1980-2006/Nov W1
 1 302: INDEX CHEMICUS_1993-200646
 3 305: Analytical Abstracts_1980-2006/Nov W1
 10 315: ChemEng & Biotec Abs_1970-2006/Oct
 Examined 150 files
 17 324: German Patents Fulltext_1967-200645
 4 331: Derwent WPI First View UD=200673
 109 340: CLAIMS(R)/US Patent_1950-06/Nov 16
 22 342: Derwent Patents Citation Indx_1978-05/200672
 1 344: Chinese Patents Abs_Jan 1985-2006/Jan
 37 345: Inpadoc/Fam.& Legal Stat_1968-2006/UD=200646
 21 347: JAPIO Dec_1976-2006/Jul(Updated 061116)
 158 348: EUROPEAN PATENTS_1978-2006/ 200646
 449 349: PCT FULLTEXT_1979-2006/UB=20061116UT=20061109
 1 353: Ei EnCompassPat(TM)_1964-200646
 1 354: Ei EnCompassLit(TM)_1965-2006/Nov W2
 2 355: Derwent Chemistry Resource UD=200671
 125 357: Derwent Biotech Res._1982-2006/Nov W3
 10 358: Current BioTech Abs_1983-2006/Jan
 2 359: Chemical Economics Handbook_2000/Jul
 1 369: New Scientist_1994-2006/Sep W2
 6 371: French Patents_1961-2002/BOPI 200209
 430 390: Beilstein Facts_2006/Q3
 6 393: Beilstein Abstracts_2006/Q3
 5653 398: Chemsearch_1957-2006/Oct
 667 399: CA SEARCH(R)_1967-2006/UD=14521
 406 434: SciSearch(R)_Cited Ref Sci_1974-1989/Dec
 990 440: Current Contents Search(R)_1990-2006/Nov 16
 1 441: ESPICOM Pharm&Med DEVICE NEWS_2006/May W4
 1 444: New England Journal of Med._1985-2006/Nov W1
 6 452: Drug Data Report_1992-2006/Aug
 7 453: Drugs of the Future_1990-2006/Aug
 1 459: Daily Essentials (Archival)_1996-2006/Nov W2
 Examined 200 files
 43 484: Periodical Abs Plustext_1986-2006/Nov W2
 1 621: Gale Group New Prod.Annou.(R)_1985-2006/Nov 17
 1 624: McGraw-Hill Publications_1985-2006/Nov 17
 Examined 250 files
 7 636: Gale Group Newsletter DB(TM)_1987-2006/Nov 20
 1 649: Gale Group Newswire ASAP(TM)_2006/Nov 06
 21 652: US Patents Fulltext_1971-1975
 668 654: US Pat.Full_1976-2006/Nov 16
 1 670: LitAlert_1973-2006/UD=200645
 2 763: Freedonia Market Res._1990-2006/Nov
 5 764: BCC Market Research_1989-2006/Oct
 1 813: PR Newswire_1987-1999/Apr 30

96 files have one or more items; file list includes 297 files.